Anoro▼ Ellipta umeclidinium/vilanterol

Product menu

Watch this short film to discover how using Anoro Ellipta as your first line maintenance therapy could offer your symptomatic adult COPD patients a strong start

DISCOVER THE HEAD-TO-HEAD DATA

What can we help you find today?

Lung Icon

See Anoro Ellipta’s head-to-head data

Anoro Ellipta is the only LAMA/LABA with head-to-head data vs. a LAMA²⁻⁵ and vs. two LAMA/LABAs.⁶ ⁷

SEE clinical DATA

Molecules icon

Explore the molecules in Anoro Ellipta

Anoro Ellipta contains two molecules specifically selected for their long duration of action, enabling once-daily dosing¹ ² ⁸⁻¹³

EXPLORE ANORO’S MOLECULES

Ellipta device icon

Discover the easy-to-use¹⁴⁻¹⁶ Ellipta device

The Ellipta device is a propellent-free, low carbon, dry powder inhaler (DPI), which can help reduce the carbon impact of inhalers.¹⁷

DISCOVER THE ELLIPTA DEVICE

What does NICE say about prescribing a LAMA/LABA in COPD?

Learn more about the NICE COPD guidelines

NICE COPD guideline recommendations are for classes of medicines, not specific products

 

Get started with Anoro Ellipta

See who might benefit from Anoro Ellipta

Order demo device

You might also be interested in…

Dosing & the Ellipta device

Learn about the easy-to-use Ellipta device

NICE COPD Guidelines

What does NICE say about prescribing LAMA/LABAs?

Molecules

Anoro Ellipta contains umeclidinium (a LAMA) and vilanterol (a LABA)

Head-to-head data

See Anoro Ellipta clinical data

References

  1. Anoro Ellipta SmPC
  2. Maleki-Yazdi M et al. Adv Ther 2016; 33:2188–2199
  3. GSK data on file RF/UCV/0112/15
  4. Maleki-Yazdi MR et al. Respir Med 2014;108:1752–1760
  5. Decramer M et al. Lancet Respir Med 2014;2:472–486.
  6. Feldman G.J et al. Adv Ther 2017; 34:2518–2533
  7. Maltais F et al. Adv Ther 2019; 36(9):2434-2449
  8. Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016;11:719–730.
  9. Laine DI. Exp Rev Clin Pharmacol 2010;3:43–53.
  10. Laine DI. J Med Chem 2009;52:2493–2505.
  11. Slack RJ et al. J Pharmacol Exp Ther 2013;344:218–230
  12. Hanania N et al. Chest 2012;142:119–127.
  13. Kempsford R et al. Pulm Pharmacol Ther 2013;26(2):256–264.
  14. van der Palen J et al. NPJ Prim Care Respir Med 2016;26:16079.
  15. Svedsater H et al. BMC Pulm Med 2013;13:72–86.
  16. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016;11:1873–1880.
  17. Hillman T, Mortimer F, Hopkinson NS. Inhaled drugs and global warming: time to shift to dry powder inhalers. BMJ. 2013 May 28;346:f3359

Adverse events should be reported. Reporting forms and information can be found at
 https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

© 2022 GSK group of companies or its licensor. ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.

Innoviva Logo

September 2022 | PM-GB-UCV-WCNT-200034 (V2.0)